alloSHRINK - Standard cHemotherapy Regimen and Immunotherapy With Allogeneic NKG2D-based CYAD-101 Chimeric Antigen Receptor T-cells

NIAID Data Ecosystem2026-03-10 收录

结直肠癌细胞免疫治疗

CAR-T临床试验

数据链接：

https://www.omicsdi.org/dataset/ecrin-mdr-crc/2285775 数据链接链接失效反馈

官方服务：

资源简介：

The purpose of the alloSHRINK study is to assess the safety, cell kinetics and clinical activity of CYAD-101 in patients with unresectable metastatic colorectal cancer administered after standard chemotherapy

创建时间：

2018-11-15

alloSHRINK - Standard cHemotherapy Regimen and Immunotherapy With Allogeneic NKG2D-based CYAD-101 Chimeric Antigen Receptor T-cells

资源简介：

相关数据集